solo per uso di ricerca
N. Cat.S1095
| Linee cellulari | Tipo di saggio | Concentrazione | Tempo di incubazione | Formulazione | Descrizione dellattività | PMID |
|---|---|---|---|---|---|---|
| H1299 | Growth inhibition assay | Inhibitory activity against H1299 human lung carcinoma cell growth, IC50=0.15 μM | ||||
| HCT116 | Growth inhibition assay | Inhibitory activity against HCT116 human colon cell growth, IC50=0.01 μM | ||||
| HCT116 | Cytotoxicity assay | Cytotoxicity against human HCT116 cells by MTT assay, IC50=0.05 μM | ||||
| human mammary epithelial cells | Cytotoxicity assay | Cytotoxicity against human mammary epithelial cells by MTT assay, IC50=1 μM | ||||
| HEK293 cells | Function assay | Inhibition of HDAC1 in HEK293 cells, IC50=0.0026 μM | ||||
| HeLa cells | Function assay | 0.3 μM | 16 h | Inhibition of HDAC4-mediated repression of MEF2-dependent transcription in HeLa cells at 0.3 uM after 16 hrs by luciferase reporter gene assay | ||
| HCT116 cells | Proliferation assay | Antiproliferative activity against human HCT116 cells by MTS assay, IC50=0.013 μM | ||||
| H1299 cells | Proliferation assay | Antiproliferative activity against human H1299 cells by MTS assay, IC50=0.161 μM | ||||
| H460 cells | Growth inhibition assay | 48 h | Growth inhibition of human H460 cells after 48 hrs by SRB assay, IC50=0.07 μM | |||
| HCT116 cells | Growth inhibition assay | 48 h | Growth inhibition of human HCT116 cells after 48 hrs by SRB assay, IC50=0.018 μM | |||
| CCRF-CEM cells | Proliferation assay | Antiproliferative activity against human CCRF-CEM cells by SRB assay, GI50=0.251 μM | ||||
| K562 cells | Proliferation assay | Antiproliferative activity against human K562 cells by SRB assay, GI50=0.55 μM | ||||
| MOLT4 cells | Proliferation assay | Antiproliferative activity against human MOLT4 cells by SRB assay, GI50=0.311 μM | ||||
| SR cells | Proliferation assay | Antiproliferative activity against human SR cells by SRB assay, GI50=2.99 μM | ||||
| A549 cells | Proliferation assay | Antiproliferative activity against human A549 cells by SRB assay, GI50=1.09 μM | ||||
| EKVX cells | Proliferation assay | Antiproliferative activity against human EKVX cells by SRB assay, GI50=1.75 μM | ||||
| HOP62 cells | Proliferation assay | Antiproliferative activity against human HOP62 cells by SRB assay, GI50=0.502 μM | ||||
| HOP92 cells | Proliferation assay | Antiproliferative activity against human HOP92 cells by SRB assay, GI50=0.199 μM | ||||
| NCI-H226 cells | Proliferation assay | Antiproliferative activity against human NCI-H226 cells by SRB assay, GI50=1.41 μM | ||||
| NCI-H23 cells | Proliferation assay | Antiproliferative activity against human NCI-H23 cells by SRB assay, GI50=1.5 μM | ||||
| NCI-H322M cells | Proliferation assay | Antiproliferative activity against human NCI-H322M cells by SRB assay, GI50=2.26 μM | ||||
| NCI-H460 cells | Proliferation assay | Antiproliferative activity against human NCI-H460 cells by SRB assay, GI50=0.7 μM | ||||
| COLO205 cells | Proliferation assay | Antiproliferative activity against human COLO205 cells by SRB assay, GI50=1.08 μM | ||||
| HCT116 cells | Proliferation assay | Antiproliferative activity against human HCT116 cells by SRB assay, GI50=0.347 μM | ||||
| HCT15 cells | Proliferation assay | Antiproliferative activity against human HCT15 cells by SRB assay, GI50=2.07 μM | ||||
| HT-29 cells | Proliferation assay | Antiproliferative activity against human HT-29 cells by SRB assay, GI50=0.566 μM | ||||
| KM12 cells | Proliferation assay | Antiproliferative activity against human KM12 cells by SRB assay, GI50=1.04 μM | ||||
| SW620 cells | Proliferation assay | Antiproliferative activity against human SW620 cells by SRB assay, GI50=0.478 μM | ||||
| SF268 cells | Proliferation assay | Antiproliferative activity against human SF268 cells by SRB assay, GI50=1.53 μM | ||||
| SF295 cells | Proliferation assay | Antiproliferative activity against human SF295 cells by SRB assay, GI50=0.743 μM | ||||
| SF539 cells | Proliferation assay | Antiproliferative activity against human SF539 cells by SRB assay, GI50=0.965 μM | ||||
| SNB19 cells | Proliferation assay | Antiproliferative activity against human SNB19 cells by SRB assay, GI50=1.53 μM | ||||
| SNB75 cells | Proliferation assay | Antiproliferative activity against human SNB75 cells by SRB assay, GI50=0.318 μM | ||||
| U251 cells | Proliferation assay | Antiproliferative activity against human U251 cells by SRB assay, GI50=0.773 μM | ||||
| LOXIMVI cells | Proliferation assay | Antiproliferative activity against human LOXIMVI cells by SRB assay, GI50=1.08 μM | ||||
| MALME-3M cells | Proliferation assay | Antiproliferative activity against human MALME-3M cells by SRB assay, GI50=0.461 μM | ||||
| M14 cells | Proliferation assay | Antiproliferative activity against human M14 cells by SRB assay, GI50=0.849 μM | ||||
| MDA-MB-435 cells | Proliferation assay | Antiproliferative activity against human MDA-MB-435 cells by SRB assay, GI50=0.537 μM | ||||
| SK-MEL-28 cells | Proliferation assay | Antiproliferative activity against human SK-MEL-28 cells by SRB assay, GI50=0.993 μM | ||||
| SK-MEL-5 cells | Proliferation assay | Antiproliferative activity against human SK-MEL-5 cells by SRB assay, GI50=0.271 μM | ||||
| UACC257 cells | Proliferation assay | Antiproliferative activity against human UACC257 cells by SRB assay, GI50=0.393 μM | ||||
| UACC62 cells | Proliferation assay | Antiproliferative activity against human UACC62 cells by SRB assay, GI50=0.379 μM | ||||
| IGROV1 cells | Proliferation assay | Antiproliferative activity against human IGROV1 cells by SRB assay, GI50=0.187 μM | ||||
| OVCAR3 cells | Proliferation assay | Antiproliferative activity against human OVCAR3 cells by SRB assay, GI50=1.11 μM | ||||
| OVCAR4 cells | Proliferation assay | Antiproliferative activity against human OVCAR4 cells by SRB assay, GI50=3.21 μM | ||||
| OVCAR5 cells | Proliferation assay | Antiproliferative activity against human OVCAR5 cells by SRB assay, GI50=0.26 μM | ||||
| OVCAR8 cells | Proliferation assay | Antiproliferative activity against human OVCAR8 cells by SRB assay, GI50=0.45 μM | ||||
| NCI/ADR-RES cells | Proliferation assay | Antiproliferative activity against human NCI/ADR-RES cells by SRB assay, GI50=0.18 μM | ||||
| SKOV3 cells | Proliferation assay | Antiproliferative activity against human SKOV3 cells by SRB assay, GI50=0.524 μM | ||||
| 786-0 cells | Proliferation assay | Antiproliferative activity against human 786-0 cells by SRB assay, GI50=2.38 μM | ||||
| A498 cells | Proliferation assay | Antiproliferative activity against human A498 cells by SRB assay, GI50=1.11 μM | ||||
| ACHN cells | Proliferation assay | Antiproliferative activity against human ACHN cells by SRB assay, GI50=1.1 μM | ||||
| Caki1 cells | Proliferation assay | Antiproliferative activity against human Caki1 cells by SRB assay, GI50=0.619 μM | ||||
| SN12C cells | Proliferation assay | Antiproliferative activity against human SN12C cells by SRB assay, GI50=3.92 μM | ||||
| TK10 cells | Proliferation assay | Antiproliferative activity against human TK10 cells by SRB assay, GI50=0.444 μM | ||||
| UO31 cells | Proliferation assay | Antiproliferative activity against human UO31 cells by SRB assay, GI50=0.452 μM | ||||
| PC3 cells | Proliferation assay | Antiproliferative activity against human PC3 cells by SRB assay, GI50=20 μM | ||||
| DU145 cells | Proliferation assay | Antiproliferative activity against human DU145 cells by SRB assay, GI50=29.9 μM | ||||
| MCF7 cells | Proliferation assay | Antiproliferative activity against human MCF7 cells by SRB assay, GI50=6.91 μM | ||||
| MDA-MB-231 cells | Proliferation assay | Antiproliferative activity against human MDA-MB-231 cells by SRB assay, GI50=31.7 μM | ||||
| Hs 578T cells | Proliferation assay | Antiproliferative activity against human Hs 578T cells by SRB assay, GI50=5.82 μM | ||||
| BT549 cells | Proliferation assay | Antiproliferative activity against human BT549 cells by SRB assay, GI50=6.04 μM | ||||
| T47D cells | Proliferation assay | Antiproliferative activity against human T47D cells by SRB assay, GI50=28.8 μM | ||||
| MDA-MB-468 cells | Proliferation assay | Antiproliferative activity against human MDA-MB-468 cells by SRB assay, GI50=5.88 μM | ||||
| NCI-H226 cells | Cytotoxicity assay | Cytotoxicity against human NCI-H226 cells, LC50=20 μM | ||||
| KM12 cells | Cytotoxicity assay | Cytotoxicity against human KM12 cells, LC50=29.9 μM | ||||
| SF295 cells | Cytotoxicity assay | Cytotoxicity against human SF295 cells, LC50=6.91 μM | ||||
| SNB19 cells | Cytotoxicity assay | Cytotoxicity against human SNB19 cells, LC50=31.7 μM | ||||
| U251 cells | Cytotoxicity assay | Cytotoxicity against human U251 cells, LC50=5.82 μM | ||||
| LOXIMVI cells | Cytotoxicity assay | Cytotoxicity against human LOXIMVI cells, LC50=6.04 μM | ||||
| MDA-MB-435 cells | Cytotoxicity assay | Cytotoxicity against human MDA-MB-435 cells, LC50=28.8 μM | ||||
| SK-MEL-28 cells | Cytotoxicity assay | Cytotoxicity against human SK-MEL-28 cells, LC50=31.9 μM | ||||
| SK-MEL-5 cells | Cytotoxicity assay | Cytotoxicity against human SK-MEL-5 cells, LC50=4.02 μM | ||||
| UACC257 cells | Cytotoxicity assay | Cytotoxicity against human UACC257 cells, LC50=44.8 μM | ||||
| UACC62 cells | Cytotoxicity assay | Cytotoxicity against human UACC62 cells, LC50=6.39 μM | ||||
| IGROV1 cells | Cytotoxicity assay | Cytotoxicity against human IGROV1 cells, LC50=48.9 μM | ||||
| OVCAR5 cells | Cytotoxicity assay | Cytotoxicity against human OVCAR5 cells, LC50=38.9 μM | ||||
| SKOV3 cells | Cytotoxicity assay | Cytotoxicity against human SKOV3 cells, LC50=28.5 μM | ||||
| A498 cells | Cytotoxicity assay | Cytotoxicity against human A498 cells, LC50=5.88 μM | ||||
| Caki1 cells | Cytotoxicity assay | Cytotoxicity against human Caki1 cells, LC50=5.79 μM | ||||
| HCT116 cells | Proliferation assay | Antiproliferative activity against human HCT116 cells, IC50=0.019 μM | ||||
| HCT116 cells | Proliferation assay | Antiproliferative activity against human HCT116 cells assessed as growth inhibition, IC50=0.019 μM | ||||
| H1299 cells | Proliferation assay | Antiproliferative activity against human H1299 cells, IC50=0.1 μM | ||||
| HCT116 cells | Proliferation assay | Inhibitory concentration against HCT116 cells proliferation, IC50=0.01 μM | ||||
| RPMI8226 cells | Proliferation assay | Antiproliferative activity against human RPMI8226 cells by SRB assay, GI50=0.523 μM | ||||
| CHO cells | Function assay | Inhibition of human ERG expressed in CHO cells by automated patch clamp electrophysiology assay, IC50=12.2 μM | ||||
| HL-60(TB) cells | Proliferation assay | Antiproliferative activity against human HL-60(TB) cells by SRB assay, GI50=0.249 μM | ||||
| RXF393 cells | Proliferation assay | Antiproliferative activity against human RXF393 cells by SRB assay, GI50=0.01 μM | ||||
| RXF393 cells | Cytotoxicity assay | Cytotoxicity against human RXF393 cells, LC50=15.3 μM | ||||
| Clicca per visualizzare più dati sperimentali sulle linee cellulari | ||||||
| Peso molecolare | 379.459 | Formula | C22H25N3O3 |
Conservazione (Dalla data di ricezione) | |
|---|---|---|---|---|---|
| N. CAS | 404951-53-7 | Scarica SDF | Conservazione delle soluzioni stock |
|
|
| Sinonimi | NVP-LAQ824 | Smiles | C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)C=CC(=O)NO | ||
|
In vitro |
DMSO
: 76 mg/mL
(200.28 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante lesperimento)
Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non cè una formulazione in vivo nella sezione Solubilità.)
Risultati del calcolo:
Concentrazione di lavoro: mg/ml;
Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.
Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nellaggiunta precedente, sia una soluzione limpida prima di procedere allaggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno dacqua calda possono essere utilizzati per facilitare la dissoluzione.
| Targets/IC50/Ki |
p21
HDAC
(Cell-free assay) 32 nM
|
|---|---|
| In vitro |
Dacinostat (LAQ824) attiva l'espressione del gene che codifica l'inibitore del ciclo cellulare p21 attivando il promotore p21 con il 50% dell'attivazione massima del promotore (AC50) di 0,30 μM. Inibisce la crescita cellulare sia di H1299, una linea di carcinoma polmonare non a piccole cellule, sia di HCT116, una linea di cellule di cancro al colon con IC50 di 0,15 μM e 0,01 μM, rispettivamente, e l'effetto antiproliferativo di questo composto è selettivo verso le linee cellulari tumorali, inducendo solo l'arresto della crescita nei fibroblasti normali. Inoltre, induce un aumento dose-dipendente della proteina p21 nelle cellule A549 e un aumento dello stato ipofosforilato del soppressore tumorale Rb. Uno studio recente mostra che LAQ824 induce cambiamenti della cromatina a livello del promotore del gene IL-10 che portano a un maggiore reclutamento dei repressori trascrizionali HDAC11 e PU.1 e inibisce la produzione di IL-10 nei macrofagi murini BALB/c.
|
| Saggio chinasico |
Saggio di istone deacetilasi in vitro
|
|
Gli enzimi HDAC vengono parzialmente purificati dal lisato cellulare H1299 mediante cromatografia a scambio ionico utilizzando la colonna Q Sepharose Fast Flow. I complessi enzimatici vengono raccolti da 500 mg di lisato cellulare totale mediante immunoprecipitazione con anticorpo policlonale cdk2 o anticorpo monoclonale cdk1/cdc2. Gli immunocomplessi vengono risospesi in tampone per chinasi (50 mM Hepes, pH 8, 10 mM MgCl2, 2,5 mM EDTA, 1 mM ditiotreitolo, 20 mM ATP, 10 mM β-glicerofosfato, 0,1 mM NaVO4, 1 mM fluoruro di sodio, 50 mM ATP, 10 μCi di [γ-32P]ATP) insieme a 1 μg di substrato proteico ricombinante pRb (cdk2) o 10 mL di miscela di istoni H1 contenente 20 μg di substrato (cdc2). Le istoni Rb e H1 fosforilate vengono risolte mediante elettroforesi e quantificate utilizzando un PhosphorImager. Questo composto, Dacinostat (LAQ824), viene utilizzato nel saggio.
|
|
| In vivo |
Dacinostat (LAQ824) produce effetti inibitori sulla crescita tumorale in modo dose-dipendente senza citotossicità generale in HCT116 e xenotrapianti di tumori del colon umano in topi nudi quando somministrato a 100 mg/kg.
|
Riferimenti |
|
Istruzioni per la manipolazione
Tel: +1-832-582-8158 Ext:3
Per qualsiasi altra domanda, si prega di lasciare un messaggio.